Home>>Histone H3K4Me2 (1-10) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt)

Histone H3K4Me2 (1-10) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt) (Synonyms: ART-K(Me2)-QTARKS, H-Ala-Arg-Thr-Lys(Me2)-Gln-Thr-Ala-Arg-Lys-Ser-OH, Histone H3 (1-10) (Lys4me2), Lys(Me2)4-Histone H3 (1-10))

Catalog No.GC43856

Histone H3K4Me2 (1-10) is an N-terminal peptide fragment of histone H3 that corresponds to amino acid residues 2-11 of the human histone H3 sequence.

Products are for research use only. Not for human use. We do not sell to patients.

Histone H3K4Me2 (1-10) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
1mg
$419.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Histone H3K4Me2 (1-10) is an N-terminal peptide fragment of histone H3 that corresponds to amino acid residues 2-11 of the human histone H3 sequence. Dimethylation of histone H3 at lysine 4 is found at active and primed, but inactive, loci. It is enriched in gene promoter regions and overlaps with transcription factor binding sites. Low tumor levels of H3K4Me2 positively correlate with decreased overall and disease-free survival in pancreatic cancer patients.

Reviews

Review for Histone H3K4Me2 (1-10) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Histone H3K4Me2 (1-10) (human, mouse, rat, porcine, bovine) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.